BioMMED Service
All BioMMED service functions are provided to LSU-based investigators on a charge back basis. Typically, LSU researchers are charged only the costs of supplies, while most of the personnel costs are provided via support of participating LSU units.
|
|
| Author: |
vtgusk |
| Dated: |
Wednesday, January 04 2006 @ 03:53 PM CST |
| Viewed: |
48,544 times |
|
BioMMED SPECIAL SEMINAR
"Targeted In Vivo Gene Delivery Via Tropism Modified Adenoviral Vectors - A Ten Year Quest for the Holy Grail"
DAVID T. CURIEL, M.D., Ph.D.
Director, Gene Therapy Center
Jeanne and Ann Griffin Chair for Women’s Cancer Research
Director, Division of Human Gene Therapy
Departments of Medicine, Obstetrics & Gynecology, Pathology and Surgery
The University of Alabama at Birmingham
Division of Human Gene Therapy
Gene Therapy Center
TUESDAY, JANUARY 24 AT 2:30 PM AT THE SVM AUDITORIUM
Dr. Curiel is visiting the LSU campus to explore collaborative research and development opportunities with BIOMMED and the Emerging Technologies Center
In addition to his multiple research activities, which are funded by NIH, Dr. Curiel is the founder of Vector Logics, Inc., a company that specializes in the use of adenoviral vectors for various gene therapy treatments.
Dr. Curiel's Research Interests
My current research interest relates to the development of vector systems for the achievement of targeted, cell-specific gene delivery. This central field mandate is being addressed via the development of adenoviral vector systems, which embody genetic capsid modifications allowing tropism modification. In addition, the parallel study of the biologic dictates of adenovirus entry is currently being endeavored.
Tropism modification via genetic capsid modification is based upon rigorous biologic characterization of vector/target cell interaction. Further, structure/function analysis of the viral capsid protein provides the basis of engineered alterations for tropism modification. At the cellular level, study of native viral receptors involves characterizing the dictates of tropism in vitro and in vivo with respect to described Ad receptors. In addition, cloning of cryptic receptors is being endeavored to identify novel Ad receptors.
Select List of Publications
Le LP, Li J, Ternovoi VV, Siegal GP, Curiel DT. Fluorescently tagged canine adenovirus via modification with protein IX-enhanced green fluorescent protein. J Gen Virol. 2005 Dec;86(Pt 12):3201-8.
Le LP, Rivera AA, Glasgow JN, Ternovoi VV, Wu H, Wang M, Smith BF, Siegal GP, Curiel DT. Infectivity enhancement for adenoviral transduction of canine osteosarcoma cells. Gene Ther. 2005 Nov 17;
Breidenbach M, Rein DT, Schondorf T, Khan KN, Herrmann I, Schmidt T, Reynolds PN, Vlodavsky I, Haviv YS, Curiel DT. A new targeting approach for breast cancer gene therapy using the Heparanase promoter. Cancer Lett. 2005 Nov 2
Mahasreshti PJ, Kataram M, Wu H, Yalavarthy LP, Carey D, Dent P, Fisher PB, Chada S, Alvarez RD, Haisma HJ, Curiel DT. Ovarian cancer targeted adenoviral-mediated mda-7/IL-24 gene therapy. Gynecol Oncol. 2005 Oct 10
Izumi M, Kawakami Y, Glasgow JN, Belousova N, Everts M, Kim-Park S, Yamamoto S, Wang M, Le LP, Reynolds PN, Curiel DT. In vivo analysis of a genetically modified adenoviral vector targeted to human CD40 using a novel transient transgenic model. J Gene Med. 2005 Sep 19
Hedley SJ, Auf der Maur A, Hohn S, Escher D, Barberis A, Glasgow JN, Douglas JT, Korokhov N, Curiel DT. An adenovirus vector with a chimeric fiber incorporating stabilized single chain antibody achieves targeted gene delivery. Gene Ther. 2005 Aug 18
Stoff-Khalili MA, Rivera AA, Glasgow JN, Le LP, Stoff A, Everts M, Tsuruta Y, Kawakami Y, Bauerschmitz GJ, Mathis JM, Pereboeva L, Seigal GP, Dall P, Curiel DT. A human adenoviral vector with a chimeric fiber from canine adenovirus type 1 results in novel expanded tropism for cancer gene therapy. Gene Ther. 2005 Dec;12(23):1696-1706
Li J, Le L, Sibley DA, Mathis JM, Curiel DT. Genetic incorporation of HSV-1 thymidine kinase into the adenovirus protein IX for functional display on the virion. Virology. 2005 Aug 1;338(2):247-58
Zhu ZB, Makhija SK, Lu B, Wang M, Rivera AA, Kim-Park S, Ulasov IV, Zhou F, Alvarez RD, Siegal GP, Curiel DT. Incorporating the survivin promoter in an infectivity enhanced CRAd-analysis of oncolysis and anti-tumor effects in vitro and in vivo. Int J Oncol. 2005 Jul;27(1):237-46
Everts M, Kim-Park SA, Preuss MA, Passineau MJ, Glasgow JN, Pereboev AV, Mahasreshti PJ, Grizzle WE, Reynolds PN, Curiel DT. Selective induction of tumor-associated antigens in murine pulmonary vasculature using double-targeted adenoviral vectors. Gene Ther. 2005 Jul;12(13):1042-8
Korokhov N, de Gruijl TD, Aldrich WA, Triozzi PL, Banerjee PT, Gillies SD, Curiel TJ, Douglas JT, Scheper RJ, Curiel DT. High Efficiency Transduction of Dendritic Cells by Adenoviral Vectors Targeted To DC-SIGN. Cancer Biol Ther. 2005 Mar;4(3):289-94. Epub 2005 Mar 20
Wu H, Han T, Belousova N, Krasnykh V, Kashentseva E, Dmitriev I, Kataram M, Mahasreshti PJ, Curiel DT. Identification of sites in adenovirus hexon for foreign peptide incorporation. J Virol. 2005 Mar;79(6):3382-90
Stoff-Khalili MA, Dall P, Curiel DT. From gene therapy to virotherapy for ovarian cancer. Minerva Ginecol. 2004 Dec;56(6):503-14. Review
Rein DT, Breidenbach M, Kirby TO, Han T, Siegal GP, Bauerschmitz GJ, Wang M, Nettelbeck DM, Tsuruta Y, Yamamoto M, Dall P, Hemminki A, Curiel DT. A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer. Clin Cancer Res. 2005 Feb 1;11(3):1327-35
Kirby TO, Rivera A, Rein D, Wang M, Ulasov I, Breidenbach M, Kataram M, Contreras JL, Krumdieck C, Yamamoto M, Rots MG, Haisma HJ, Alvarez RD, Mahasreshti PJ, Curiel DT. A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity. Clin Cancer Res. 2004 Dec 15;10(24):8697-703.
Ternovoi VV, Le LP, Belousova N, Smith BF, Siegal GP, Curiel DT. Productive replication of human adenovirus type 5 in canine cells. J Virol. 2005 Jan;79(2):1308-11
Breidenbach M, Rein DT, Everts M, Glasgow JN, Wang M, Passineau MJ, Alvarez RD, Korokhov N, Curiel DT. Mesothelin-mediated targeting of adenoviral vectors for ovarian cancer gene therapy. Gene Ther. 2005 Jan;12(2):187-93
Volk AL, Rivera AA, Page GP, Salazar-Gonzalez JF, Nettelbeck DM, Matthews QL, Curiel DT. Employment of microarray analysis to characterize biologic differences associated with tropism-modified adenoviral vectors: utilization of non-native cellular entry pathways. Cancer Gene Ther. 2005 Feb;12(2):162-74
Contreras JL, Xie D, Mays J, Smyth CA, Eckstein C, Rahemtulla FG, Young CJ, Anthony Thompson J, Bilbao G, Curiel DT, Eckhoff DE. A novel approach to xenotransplantation combining surface engineering and genetic modification of isolated adult porcine islets. Surgery. 2004 Sep;136(3):537-47
Pereboeva L, Komarova S, Mahasreshti PJ, Curiel DT. Fiber-mosaic adenovirus as a novel approach to design genetically modified adenoviral vectors. Virus Res. 2004 Sep 15;105(1):35-46
Le LP, Everts M, Dmitriev IP, Davydova JG, Yamamoto M, Curiel DT. Fluorescently labeled adenovirus with pIX-EGFP for vector detection. Mol Imaging. 2004 Apr;3(2):105-16
|
Trackback URL for this entry: http://biommed.lsu.edu/trackback.php?id=20060104155307643
No trackback comments for this entry.
|
|
User Functions
Don't have an account yet? Sign up as a New User
Lost your password?
BioMMED IMAGESThese are images of BioMMED laboratory personnel.
Group Pictures
Who's OnlineGuest Users: 8
|
